Polycationic peptide coatings and methods of making the same

• US 7,794,743 B2
• Filed: 09/02/2005
• Issued: 09/14/2010
• Est. Priority Date: 06/21/2002
• Status: Active Grant

• Current Assignee: Advanced Cardiovascular Systems Incorporated
• Original Assignee: Advanced Cardiovascular Systems Incorporated
• Inventors: Simhambhatla, Murthy V., Pacetti, Stephen D., Ding, Ni
• Primary Examiner(s): Azpuru; Carlos A
• Application Number:
  US11/218,654
• Publication Number:
  US 20060062821A1
• Time in Patent Office: 1,838 Days
• Field of Search: None
• US Class Current: 424/426
• CPC Class Codes: A61L 2300/114 Nitric oxide, i.e. NO
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/622 Microcapsules
• CPC Class Codes: A61L 2300/626 Liposomes, micelles, vesicles
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 77/04 Polyamides derived from alpha-amino carboxylic acids C08L77/10 takes precedence

Abstract

Polycationic peptide coatings for implantable medical devices and methods of making the same are described. The methods include applying an emulsion on the device, the emulsion including a polymer and a polycationic peptide. Other methods include incorporation of the polycationic peptide in microspheres and liposomes.

Claims

1. An implantable medical device comprising a coating, wherein the coating includes a dispersed particle phase comprising a polycationic peptide.

2. The implantable medical device of claim 1, comprising a stent.

3. The implantable medical device of claim 1, wherein the coating comprises a polymer.

4. The implantable medical device of claim 1, wherein the coating comprises a biodegradable polymer.

5. The implantable medical device of claim 2, wherein the stent comprises a biodegradable component.

6. The implantable medical device of claim 1, wherein the coating comprises an acrylic polymer, a vinyl polymer, a polyurethane, or a combination thereof.

7. The implantable medical device of claim 6, wherein the acrylic polymer comprises a component selected from a group consisting of poly(butyl methacrylate) and poly(methyl methacrylate).

8. The implantable medical device of claim 6, wherein the vinyl polymer comprises a component selected from a group consisting of poly(ethylene-co-vinyl alcohol) and poly(vinyl acetate).

9. The implantable medical device of claim 1, wherein the dispersed particle phase comprises a microsphere or liposome.

10. The implantable medical device of claim 9, wherein the microsphere comprises a biodegradable polymer.

11. The implantable medical device of claim 9, wherein the liposome comprises an amphophilic substance.

12. The implantable medical device of claim 11, wherein the amphophilic substance comprises a phospholipid, phosphatidylcholine, shingomyelin, lipids containing polymerized portions of poly(ethylene glycol), or combinations thereof.

13. The implantable medical device of claim 1, wherein the polycationic peptide includes poly(L-arginine), poly(D-arginine), poly(D,L-arginine), a mixture of poly(L-arginine) and poly(D-arginine), poly(L-lysine), poly(D-lysine), poly(δ

-guanidino-α

-aminobutyric acid), or mixtures thereof.

14. The implantable medical device of claim 1, wherein the polycationic peptide comprises hepta-arginine.

15. The implantable medical device of claim 1, comprising a diffusion-limiting hydrophobic polymer topcoat.

16. The implantable medical device of claim 1, wherein the coating comprises an agent.

17. The implantable medical device of claim 16, wherein the agent is selected from a group consisting of bioactive agents, biobeneficial agents, diagnostic agents, plasticizing agents, and any prodrugs, codrugs, metabolites, analogs, homologues, congeners, derivatives, salts, and combinations thereof.

18. The implantable medical device of claim 16, wherein the agent is selected from a group consisting of poly(alkylene glycols), phosphorylcholine, poly(N-vinyl pyrrolidone), poly(ethylene oxide), poly(acrylamide methyl propane sulfonic acid), poly(styrene sulfonate), polysaccharides, poly(ester amides), peptides, non-thrombotics, antimicrobials, nitric oxide donors, free radical scavengers, and any prodrugs, codrugs, metabolites, analogs, homologues, congeners, derivatives, salts, and combinations thereof.

19. The implantable medical device of claim 16, wherein the agent is selected from a group consisting of rapamycin, methyl rapamycin, everolimus, pimecrolimus, 42-Epi-(tetrazoylyl)rapamycin (ABT-578), tacrolimus, and any prodrugs, codrugs, metabolites, analogs, homologues, congeners, derivatives, salts, and combinations thereof.

20. The implantable medical device of claim 16, wherein the agent is selected from a group consisting of imatinib mesylate, paclitaxel, docetaxel, midostaurin, and any prodrugs, codrugs, metabolites, analogs, homologues, congeners, derivatives, salts, and combinations thereof.

21. The implantable medical device of claim 16, wherein the agent is selected from a group consisting of estradiol, clobetasol, idoxifen, tazarotene, and any prodrugs, codrugs, metabolites, analogs, homologues, congeners, derivatives, salts, and combinations thereof.

22. The implantable medical device of claim 16, wherein the agent is a combination of agents selected from a group consisting of everolimus and clobetasol;

tacrolimus and rapamycin;

tacrolimus and everolimus;

rapamycin and paclitaxel; and

, combinations thereof.

23. The implantable medical device of claim 1, wherein the particle size ranges from about 0.01 μ

m to about 5 μ

m in diameter.

24. A method of delivering an agent to a mammalian tissue, wherein the method comprises contacting the stent of claim 2 with the mammalian tissue under in vivo conditions.

25. The method of claim 24, wherein the tissue comprises a vascular tissue.

26. The method of claim 24, wherein the agent comprises hepta-arginine.

27. A method of preventing or treating a disease comprising implanting the stent of claim 2 in a vascular lumen.

28. The method of claim 27, wherein the disease comprises a vascular disease comprising restenosis, vulnerable plaque, or a combination thereof.

29. The method of claim 27, wherein the coating comprises hepta-arginine.